Methods for detecting predisposition to cancer at the MTS gene
AssigneesUniversity of Utah Research Foundation, Myriad Genetics, Inc.
InventorsMark H. Skolnick, Lisa A. Cannon-Albright, Alexander Kamb
Life of this patent
Estimating the term…
Loading patent…
AssigneesUniversity of Utah Research Foundation, Myriad Genetics, Inc.
InventorsMark H. Skolnick, Lisa A. Cannon-Albright, Alexander Kamb
Estimating the term…
The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
A method for diagnosing a polymorphism associated with predisposition for cancer selected from the group consisting of melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum, in a human comprising:
A method for confirming the lack of a predisposition for cancer at the Multiple Tumor Suppressor locus in a human, comprising:
Dependencies are inferred from the claim text.